Download PDF
Thromb Haemost 1997; 77(05): 1031-1033
DOI: 10.1055/s-0038-1656098
Scientific and Standardization Committee Communication
Schattauer GmbH Stuttgart

A Reference Material for Harmonisation of D-Dimer Assays

Willem Nieuwenhuizen
The Gaubius Laboratory, Leiden, The Netherlands, on behalf of the Fibrinogen Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis
› Author Affiliations
Further Information

Publication History

Publication Date:
11 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The term “D-dimer assay” suggests, that these assays report the concentrations of the end-stage degradation product of crosslinked fibrin. This hardly occurs in patients. Degradation products of crosslinked fibrin rather occur with a wide range of molecular weights, and comprise various numbers of the D-dimer motif. Moreover, the numerical values obtained with different “D-dimer” assays vary widely. The variations are probably due to differences in reactivity of the various monoclonal antibodies used with the various D-dimer containing degradation products as they occur in patients; and to the various calibrators with a value assigned by the manufacturers. For the reasons indicated above a calibrator in the strict sense (e.g. pure D-dimer) is not feasible. This study shows that: it appears feasible to generate a conversion factor for each of the “D-dimer” assays studied, which will make the widely varying results obtained with these kits comparable; that the conversion factors can be based on a pool of real patient samples; and that the conversion factors are pool-independent.

The next and final step in this study is to prepare and make available an international reference material for use by manufacturers and others facing a comparison problem. This is being carried out, in collaboration with the NIBSC (Dr. P. Gaffney), and the material is expected to be available in early 1997.

 

  • References

  • 1 Kudryk B, Reuterby J, Blombäck B. Adsorption of plasmic fragment D to thrombin modified fibrinogen-Sepharose. Thromb Res 1973; 2: 297-304
    CrossrefPubMedGoogle Scholar
  • 2 Blombäck B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501
    CrossrefPubMedGoogle Scholar
  • 3 Budzynski AZ, Olexa SA, Pandya BV. Fibrin polymerisation sites in fibrinogen and fibrin fragments. Ann NY Acad Sci 1983; 408: 301-314
    CrossrefPubMedGoogle Scholar
  • 4 Hermans J, McDonagh J. Fibrin: structure and interaction. Semin Thromb Haemostas 1982; 8: 11-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Mosesson MW, Siebenlist KR, Hainfeld JF, Wall JS. The covalent structure of factor XIIIa-crosslinked fibrinogen fibrils. J Struct Biol 1995; 115: 88-101
    CrossrefPubMedGoogle Scholar
  • 6 Gaffney PJ. FDP. Lancet 1972; 02: 1422
    PubMedGoogle Scholar
  • 7 Francis CW, Marder VJ, Barlow GH. Plasmin degradation of crosslinked fibrin. J Clin Invest 1980; 66: 1033-1043
    CrossrefPubMedGoogle Scholar
  • 8 Kroneman H, Nieuwenhuizen W, Knot EAR. Monoclonal antibody-based plasma assays for fibrin(ogen) and derivatives, and their clinical relevance. Blood Coagul Fibrinol 1990; 1: 91-111
    CrossrefPubMedGoogle Scholar
  • 9 Koopman J, Haverkate F, Koppert PW, Nieuwenhuizen W, Brommer EJP, van der Werf WGC. New immunoassay for fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987; 109: 75-84
    PubMedGoogle Scholar
  • 10 Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: Analysis of standardization issues and target antigens in plasma. Brit J Haematol 1995; 90: 187-194
    CrossrefPubMedGoogle Scholar